pomalidomide,dexamethasone,isatuximab
sanofi,bms
congress #ims2022 | paul richardson presents data on final os analysis of the phase iii icaria-mm trial of isa+pd vs pd in patients with r/r #mm. the results demonstrate a clinically meaningful benefit and manageable safety profile for isa-pd treatment. 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma